Bringing the Oncology Community Together

Dr. Weber Explores Nivolumab in Advanced Melanoma

Jeffrey S. Weber, MD, PhD
Published Online: Friday, June 21, 2013
Jeffrey S. Weber, MD, PhD, the director of the Donald A. Adam Comprehensive Melanoma Research Center at the Moffitt Cancer Center and Research Institute in Tampa, FL, describes a single institution phase I/II trial exploring the anti-PD-1 antibody nivolumab in combination with a peptide vaccine for patients with unresectable melanoma.

The trial divided 90 patients with unresectable melanoma who were naïve or refractory to ipilimumab into several cohorts to allow for individual analyses. Overall, Weber notes, response rates were similar between patients who were ipilimumab naive (28%) and those who were refractory (32%). Additionally, correlative immune assays were performed to examine possible biomarkers, such as the affect of PD-L1 positivity on response.

The examination of PD-L1 was undertaken to reproduce earlier work suggesting that PD-L1 was a predictive marker of response for nivolumab. Overall, an association between tumor PD-L1 and response was discovered; however, this association was not definitive. In general, Weber notes, patients who did not test positive for PD-L1 still responded to nivolumab.

Related Articles
Novel Immunotherapeutic Safe and Effective in Early-Phase Melanoma Study
A novel immunotherapeutic known as IMCgp100 induced clinical responses with manageable toxicity in patients with advanced melanoma
Long-Term Outcomes Support Sentinel-Node Biopsy for Staging Melanoma
A 10-year follow-up study of regional melanoma staging strategies found that patients who underwent sentinel-node biopsies had significantly greater disease-free survival rates (DFSRs) compared with patients monitored through nodal observation.
Durable T-VEC Responses Fail to Prolong Survival in Updated Analysis
Talimogene laherparepvec significantly improved durable response rates but failed to extend overall survival in patients with advanced melanoma.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.